ClinicalTrials.gg
TerminatedNCT01978301Updated May 15, 2017

Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars

A Phase 1 interventional study of Triamcinolone acetonide and Placebo in Fibrosis, sponsored by GlaxoSmithKline. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2017-05-15.

Primary conditionKeloidRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Keloid
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's title name Keloid, a narrower term within Fibrosis.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Diagnostic

Why this study was terminated
Temporary hold on recruitment during staff changes at the site

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a 3-arm randomised clinical enabling study, with no investigational product. Keloid patients who are scheduled for surgical excision of one or more keloid scars (up to nine) will be recruited to the study. The aim is to investigate how collagen synthesis within keloid scars is affected by the current approved steroid treatment for keloids, triamcinolone acetonide (TAC). The primary endpoint will be fractional collagen synthesis in keloids which have received intra-lesional injections of TAC, placebo or no treatment prior to their removal. Fractional collagen synthesis will be determined using an established isotope/mass spectrometric technique which measures levels of deuterium incorporation into collagen following administration of heavy water to the subject. In addition; keloid tissue samples will be evaluated post surgery to identify further biomarkers of extracellular matrix synthesis and degradation for application in future clinical studies. Subjects will complete a screening visit and will then be randomised to receive three intra-lesional injections of TAC or placebo, or no treatment, at an interval of 2-3 weeks. Subjects will be randomised to different treatment sequences depending on the number of keloids they have scheduled for surgery, in such a way that subjects with multiple keloids will receive different arms of study treatment in their different keloids. Planned surgery for removal of their keloid(s) will be performed at week 6-8. All subjects will receive daily heavy water (Deuterium oxide) administration (twice daily or thrice daily as directed), with the first dose being taken at the Week 2 clinic visit and the final dose being taken on the day prior to surgery. A follow-up visit will be conducted at 1-4 weeks post-surgery.

02

Conditions studied

  • Fibrosis

Browse trials for

Keywords

  • triamcinolone acetonide (TAC)
  • heavy water
  • fibrosis
  • deuterium
  • collagen degradation
  • collagen synthesis
  • Keloid
  • patient
03

In context

Keloid Reclassified

139 studies on the registry are indexed under Keloid; 26 are open to participants now.

This study's enrollment of 9 is below the median of 30 across 110 interventional studies indexed under Keloid.

Browse Keloid studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Keloid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects have at least one keloid scar scheduled for removal as part of their normal course of treatment
  • Males or females aged between 18 and 55 years of age inclusive, at the time of signing the .
  • A female subject is eligible to participate if she is of: with negative pregnancy test as determined by urine human chorionic gonadotropin (hCG) test at screening, AND; agrees not to become pregnant during the course of the study and for at least 1 month after completion of heavy water consumption; OR is of non child-bearing potential
  • Male subjects must agree not to father a child during the study and for at least 1 month after completion of heavy water consumption.
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion criteria

Exclusion Criteria:

  • Keloids to be randomised must not have received treatment for at least two months prior to screening.
  • Evidence of other skin conditions or scarring in the region of keloid scaring (including but not limited to: hypertrophic scars, eczema, psoriasis, etc.) unless the Investigator, in consultation with the GSK medical monitor, agree that the condition is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • History of regular alcohol consumption that could preclude safe completion of the study.
  • History of sensitivity to corticosteroids or history of drug or other allergy that, in the opinion of the investigator or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation.
  • Subjects currently receiving oral corticosteroids.
  • Subjects with a recent history of tuberculosis (TB) (within last three years).
  • Evidence or recent history (past two weeks) of any infection (viral, bacterial, fungal, protozoan, or helminthic).
  • History of recurrent fungal infection.
  • Lactating females.
  • The subject has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    Triamcinolone acetonide

    Subjects will receive three intra-lesional injections of triamcinolone acetonide in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence

    Drug: Triamcinolone acetonide

  • Placebo comparator
    Placebo

    Subjects will receive three intra-lesional injections of placebo in their qualifying keloid(s), at 2-3 weeks intervals, according to their assigned treatment sequence.

    Drug: Placebo

  • No intervention
    No treatment

    Keloid(s) assigned 'No Treatment' will not receive any treatment.

Interventions

  • Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).

  • DrugPlacebo

    Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).

06

What researchers measure

Primary outcomes

  1. Fractional synthesis of collagen in keloid scars

    Post surgical excision of keloids, tissue samples will be obtained by snap frozen biopsies. Fractional synthesis of collagen (that is, the fraction of the collagen that is newly synthesised during the labelling period) will be determined using mass spectrometry which measures the levels of deuterium incorporation into hydroxyproline or alanine in the collagen from the excised tissue samples, following administration of heavy water (Deuterium oxide) to the subject

    Time frame: Week 6-8

Secondary outcomes

  1. Keloid scar volume before first dose and immediately prior to surgery

    For each keloid under evaluation, the keloid volume will be measured using three-dimensional (3D) photography

    Time frame: Day 1 and Week 6-8

  2. Keloid scar surface area before first dose and immediately prior to surgery

    For each keloid under evaluation, the keloid surface area will be measured using 3D photography

    Time frame: Day 1 and Week 6-8

  3. Keloid scar length and height before first dose and immediately prior to surgery

    For each keloid under evaluation, the keloid length and height will be measured using 3D photography

    Time frame: Day 1 and Week 6-8

  4. Keloid scar vascularity before first dose and immediately prior to surgery

    For each keloid under evaluation, the keloid vascularity will be measured by laser Doppler

    Time frame: Day 1 and Week 6-8

07

Study locations

1 site
  • GSK Investigational Site
    London, E1 2AT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Feb 2015, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2013
First posted
Nov 7, 2013
StartActual
Apr 15, 2014
Primary completionActual
Feb 5, 2015
CompletionActual
Feb 5, 2015
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01978301
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 7, 2013
Start date
Apr 15, 2014
Primary completion
Feb 5, 2015
Completion
Feb 5, 2015
Last update
May 15, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion